MsC and PhD in Biochemistry at the University Miguel Hernández. During her PhD she focused on the molecular bases of neuronal regeneration. After that, she started working in the Department of Genetics as a postdoctoral researcher, where she dedicated more than 13 years to the research of pathogenesis mechanisms and therapeutic approaches in rare neuromuscular diseases. During this period, she produced 22 scientific articles and 7 related patents. She was PI in 5 competitive projects and supervised 4 PhD projects. During the initial steps of the Project that led to Arthex foundation, she was awarded several valorisation grants (FIPSE estudios de Valorización, Caixaimpulse) including training in business management and development, IPP, financials and regulatory issues. She cofounded Arthex in December 2019 and has been CEO since then.
Dr. Rubén Artero. Advisor and Co-founder
Msc and PhD in Biochemistry, full professor of Genetics at the University of Valencia. Leader of the translational genomics lab in the UV. His laboratory is focused on the molecular basis of muscle atrophy in myotonic dystrophy and in identifying appropriate therapeutic targets and candidate drugs using cell, animal and bioinformatics approaches. During his doctoral degree, he discovered the muscleblind gene, the founding member of the MBNL family of proteins, he received six years of postdoctoral training at the Memorial Sloan-Kettering Cancer Center in New York studying Drosophila myogenesis.
Dr. Pedro Fernández. Director of Operations
Msc in Biochemistry, PhD for the Polytechnic University of Valencia and postgraduate in R & D management, internationally accredited RTTP by ATTP. He has 7 years of experience in technology transfer, project management and R&D management. Pedro also co-founded the company Tricopharming, which researches the different medicinal properties of trichomes in plants. At Arthex, he is responsible for the management of the scientific area of the company including Intellectual Property issues as well as strategic partnerships. Since 2017, Pedro has also worked as a lecturer at the Department of Biotechnology of the Universitat Politècnica de València.
Sheila Soriano. Product Manager at Arthex Biotech
Her main work is focused on product development, coordination of the CMC part of the business project, as well as bioanalytical studies for Arthex research programs.
She graduated in Chemistry from Zaragoza University, where her main focus was researching the determination of silver nanoparticles in food additives for animals. Her studies focused on Analytical Sciences at Università degli studi di Messina, where she studied the interaction between As (V) and aluminium in aqueous solution. She also completed a postgraduate degree in Health and Safety and a master’s degree in Big data and Business Intelligence.
Evidently, Sheila combines a specific technical profile with skills related to the business world, its management and promotion.
Marc graduated from the University of Valencia with a degree in Biotechnology. As part of his degree, he studied DNA manipulation and research techniques, as well as testing on protein analysis, disease models and confocal microscopy.
Marc, joined us after his experience in the Translational Genomics Research Laboratory at ERI Biotecmed (University of Valencia). This is the academic group where our foundational science comes from.
Description of the advisory board members:
Dr. Ramón Eritja. Institute of Advance Chemistry of Catalonia
Director of the Nucleic Acids Chemistry Group at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC). He was a group leader and director of DNA synthesis facilities at the European Molecular Biology Laboratory (EMBL), Heidelberg (Germany) 1994-1999. He is a CSIC research professor in Barcelona from 2000 to the present. From 2012 to 2017 he was Director of IQAC-CSIC. He has remarkable contacts with several companies dedicated to RNA and DNA synthesis and works as advisor for companies developing therapeutic oligonucleotides.
Dr. Nicholas Johnson. Virginia Commonwealth University.
Nicholas E. Johnson, MD, MSCI, FAAN is an associate professor of Neurology and Human and Molecular Genetics and vice chair of research in Neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester.
His laboratory is focused on identifying the pathogenesis of limb girdle muscular dystrophy, myotonic dystrophy, andfacioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders.
Dr. Guillaume Bassez
Dr. Bassez is an associate professor in adult neurology at Sorbonne University and the coordinator of “DM-Scope” the French Myotonic Dystrophy Registry, which is currently the largest data registry dedicated to myotonic dystrophy (DM1 and DM2).
The DM-scope registry collects clinical, sociodemographic and lifestyle data of individuals diagnosed with myotonic dystrophy by expert centres. The registry gathers more than 3000 DM patients. It has supported more than 10 research studies which helped define clinical characteristics, prognosis and formulate treatment recommendations.
He leads the REDs (Repeat Expansion & Myotonic Dystrophy) research team at the Institute of Myology at Pitié-Salpêtrière Hospital in Paris. His research topic encompasses the characterization of symptoms and natural history studies, the validation of outcome measures for clinical trials and biomarker identification.
Dr. Eric Marcusson
Eric Marcusson, Ph. D. is a scientific director with extensive experience in preclinical drug discovery in the field of RNA therapeutics. Throughout his career he has worked with innovative technologies to identify genes that make effective targets for specific molecularly-targeted therapies and helped to drive these therapies into the clinic. He has played major roles in starting new therapeutic companies and has a passion for evaluating novel technologies that may lead to more efficient drug discovery platforms and effective treatments for patients in need.
Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists. He is also co-founder and CSO of Providence Therapeutics, specialized in mRNA vaccines. Previously, he played the role of scientific director at leading companies in the RNA therapeutics field, such as Regulus Therapeutics and Ionis Pharmaceuticals. In addition to his experience bringing novel RNA drugs to the clinic, he has been involved in business development that led to multiple alliances with large pharmaceutical companies and medical centers for drug discovery and development.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.